Objective Patients with lupus nephritis receiving intravenous cyclophosphamide (IVCY) 
Introduction

Intravenous cyclophosphamide (IVCY) therapy has been accepted internationally for the treatment of lupus nephritis, ever since it was first reported about twenty years ago
and further studies (2) (3) (4) (5) (1) (2) (3) (4) (5) . The results of the first RCT revealed the efficacy of this therapy (1, 2) , and the second RCT revealed the efficacy of long-term therapy (3) . Further, the results of the third RCT revealed the efficacy of the combination therapy with steroid pulse therapy (4, 5) . IVCY studies have mainly been conducted using American subjects consisting of Caucasians and Afro-Americans. However, since patients with severe nephritis and obesity were frequently observed among the American subjects who were mainly enrolled in these studies, the result is not necessarily adequate for Japanese subjects. Indeed, in European subjects, the Euro Lupus Nephritis Trial (ELNT) showed that even low dose IVCY therapy is capable of achieving sufficient efficacy (6) . Thus, we postulate that IVCY therapy has some risk for adverse effects, therefore we can not simply apply the results of the NIH study to Japanese subjects. However, there have been only a few studies concerning the efficacy of IVCY in Japanese patients. Our previous study first demonstrated the efficacy in Japanese patients, and these results were related to the lymphocyte marker (7) . However (10) , as patients with no nephritis at the time of the initial diagnosis and who had nephritis during the disease course. These initial main manifestations were defined in our previous study (10 
have revealed its efficacy. Most studies concerned with this therapy have been conducted as randomized controlled trials (RCT) at the National Institutes of Health (NIH)
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05). The number of drop-out cases was high in Group B (6 cases).
Long-term prognosis of patients with remission
Next, the long-term prognosis of patients with remission Null hypothesis : Group(1) =Group(2)=Group(3) (p=0.00471) 
F i g u r e 1 . L o n g -t e r m p r o g n o s i s o f p a t i e n t s wi t h r e mi s s i o n wi t h I VCY t h e r a p y . Gr o u p A i n c l u d e s p a t i e n t s wi t h f r e s h p at i e n t s wi t h f r e s h n e p h r i t i s , Gr o u p B i n c l u d e s p a t i e n t s wi t h r el a p s e n e p h r i t i s a n d Gr o u p C i n c l u d e s p a t i e n t s wi t h n e p h r i t i s a s t h e t r a n s i t i o n o f t h e ma i n c l i n i c a l ma n i f e s t a t i o n . T h e r emi s s i o n r a t e o f Gr o u p B wa s s i g n i f i c a n t l y d e c r e a s e d a s c o mp a r e d wi t h Gr o u p A o r C ( L o g Ra n k t e s t : p < 0 . 0 5 ) .
F i g u r e 2 . T h e r e l a t i o n b e t we e n r e mi s s i o n a n d r e n a l p r o g n o s i s . T h e r a t e o f wi t h o u t d o u b l e c r e a t i n i n e l e v e l s i n p a t i e n t s wi t h r e l a p s e a f t e r r e mi s s i o n ( Gr o u p ( 2 ) ) o r wi t h o u t r e mi s s i o n ( Gr o u p ( 3 ) ) s i g n i f i c a n t l y d e c r e a s e d a s c o mp a r e d wi t h p a t i e n t s wi t h r e mi s s i o n ( Gr o u p ( 1 ) ) ( L o g Ra n k t e s t p <
T a b l e 1 . E f f i c a c y o f I CVY a f t e r S i x Mo n t h s o f Ad mi n i s t r a t i o n
F i g u r e 3 . T h e r e l a t i o n b e t we e n t h e t o t a l d o s e o f I VCY a n d r e mi s s i o n .
T h e r e wa s n o s i g n i f i c a n t d i f f e r e n c e b e t we e n p a t i e n t s r e c e i v i n g mo r e o r l e s s t h a n 2 g o f I VCY. Null hypothesis : Above 2g = Below 2g (p=0.918) Fig. 3 (Fig. 4) (11) . Although good efficacy of IVCY is expected in patients with any of these courses (11, 12) (16) . In our previous study (12) and the study of the NIH group (1, 2) 
F i g u r e 4 . T h e r e l a t i o n b e t we e n t h e c o mb i n a t i o n t h e r a p y wi t h s t e r o i d p u l s e t h e r a p y . T h e r e wa s n o s i g n i f i c a n t d i f f e r e n c e b e t we e n p a t i e n t s r e c e i v i n g s t e r o i d p u l s e t h e r a p y a n d t h o s e wi t h o u t .
T a b l e 2 . T h e Re l a t i o n b e t we e n P r o g n o s i s a n d Cl i n i c a l P r o f i l e o f t h e P a t i e n t
The relation to total dose or combination therapy
Next, the relation to total dose administered was investigated, and the patients were divided into two groups as follows: low dose group (received less than 2 g as total dose) and high dose group (received more than 2 g). As to the results, there was no difference in the efficacy (data not shown). As shown in
